Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6081)	10/15/1998 8:35:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Celebra has been re-named Celebrex: ''They have next year's potential blockbuster drug,'' said Erik Anderson, a portfolio manager with Sit Investment, which holds 676,000 Monsanto shares. ''They have all of these new products.'' The name of the drug, expected to start sales in 1999, has been changed to Celebrex from Celebra to avoid possible confusion with Celexa, an antidepressant, Monsanto said. Celexa is sold by Forest Laboratories Inc. Pfizer's Interest And, Pfizer has shown strong interest in the new Monsanto drug, which can treat pain and swelling without irritating the stomach as existing painkillers do. Pfizer has made about $240 million in payments over the past six months for marketing rights to the drug, said Hemant Shah, an independent drug analyst. ''I've never seen a payment like that ever for any drug,'' Shah said. ''Pfizer must think Celebra has a potential of incredible proportions.'' quote.bloomberg.com